



# Continuing Professional Development - Thoracic oncology

# Module 1. Carcinogenesis, immunology and defence mechanisms

- 1. Carcinogenesis
  - 1.1. Basic principles of carcinogenesis, including the dysplastic lesion-carcinoma *in situ*-invasive lesion sequence
  - 1.2. Tumour immunology
  - 1.3. Basic principles related to tumour immunology, including the general structure of innate and adaptive immune recognition and immune responses in humans as well as the elimination-equilibrium-escape sequence
- 2. Hallmarks of cancer
  - 2.1. Self-sufficiency in growth signals
  - 2.2. Insensitivity to anti-growth signals
  - 2.3. Evasion from programmed cell death (apoptosis)
  - 2.4. Limitless replicative potential
  - 2.5. Sustained angiogenesis
  - 2.6. Tissue invasion and metastasis
  - 2.7. Deregulated metabolism
  - 2.8. Evasion from the immune system
  - 2.9. Genome instability
  - 2.10. Inflammation

## Module 2. Tobacco - risk factors and epidemiology

- 1. Current epidemiology of active and passive smoking, heated tobacco products and smokeless tobacco products as well as other smoked or vape-related products worldwide and nationally in relation to thoracic malignancies
- 2. Pathogenic mechanisms of active and passive smoking, heated tobacco products and smokeless tobacco products related to thoracic malignancies
- 3. Socio-economic and cultural aspects of tobacco consumption related to thoracic malignancies

#### Module 3. Indoor and outdoor pollution

1. Basic principles of indoor and outdoor pollution related to thoracic malignancies

#### Module 4. Respiratory hazards associated with occupational factors

1. Occupational carcinogens that cause thoracic malignancies; causal relationships

#### Module 5. Asbestos-related diseases

- 1. Asbestos-related diseases
- 2. Non-malignant pleural manifestations (acute benign pleural effusions, rounded atelectasis, diffuse pleural thickening and pleural plaques)
- 3. Malignant pleural mesothelioma
- 4. Asbestosis
- 5. Lung cancer related to asbestos

#### Module 6. Lung cancer screening

1. Low dose computed tomography (CT) as an evidence-based measure for lung cancer screening in high risk populations

## Module 7. Signs and symptoms

- 1. Symptoms as potential indicators of thoracic oncological disease:
  - 1.1. Dyspnoea
  - 1.2. Dysphagia
  - 1.3. Chest pain
  - 1.4. Bone pain
  - 1.5. Headache
  - 1.6. Tiredness





- 1.7. Cough
- 1.8. Haemoptysis
- 1.9. Wheezing
- 1.10. Stridor
- 1.11. Hoarseness
- 1.12. Weight loss
- 1.13. Diaphragmatic elevation
- 1.14. Pleural effusion
- 1.15. Pericardial effusion
- 1.16. Superior vena cava syndrome
- 1.17. Pancoast syndrome
- 1.18. Horner syndrome
- 1.19. Enlarged, non-moveable and/or indurated cervical, supraclavicular or nuchal lymph nodes
- 1.20. Neurological signs or symptoms
- 1.21. Paraneoplastic skin disorders (erythema gyratum repens, acanthosis nigérians etc)
- 2. Awareness of paraneoplastic syndromes including:
  - 2.1. Cachexia
  - 2.2. Hypercalcemia
  - 2.3. Thromboses and pulmonary embolism
  - 2.4. Syndrome of inappropriate antidiuretic hormone (hyponatremia)
  - 2.5. Ectopic adrenocorticotropic hormone syndrome
  - 2.6. Lambert-Eaton syndrome
  - 2.7. Clubbing and periostitis

#### Module 8. Imaging techniques

- 1. Chest X-ray
- 2. Thoracic ultrasound
- 3. Computed tomography (CT) scan
- 4. Positron emission tomography (PET)
- 5. PET-CT
- 6. Ventilation perfusion scan
- 7. Bone scan
- 8. Octreotide scan
- 9. Single-photon emission computed tomography (SPECT)
- 10. Magnetic resonance imaging (MRI)
- 11. Basic principles of each imaging modality as well as basic radioprotection measures

## Module 9. Bronchoscopy

- 1. Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for diagnostic flexible and rigid bronchoscopy and diagnostic techniques in the context of thoracic oncology
- 2. Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for therapeutic bronchoscopy in the context of thoracic oncology (stents, cryotherapy, laser techniques, argon plasma, brachytherapy, electrocautery and photodynamic therapy)
- 3. Principles of discontinuation and bridging of anticoagulants
- 4. Principles of sedation
- 5. Sampling and handling of probes

#### Module 10. Advanced endoscopy

- 1. Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for each procedure (including EBUS/EUS) in the context of thoracic oncology
- 2. Different ranges of the methods
- 3. Basic lymph node anatomy/stations of the mediastinum
- 4. Principles of discontinuation and bridging of anticoagulants





- 5. Principles of sedation
- 6. Sampling and handling of probes
- 7. Navigation bronchoscopy
- 8. Nodule Biopsy

## Module 11. Thoracoscopy

- 1. Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for diagnostic thoracoscopy in the context of thoracic oncology
- 2. Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for therapeutic thoracoscopy in the context of thoracic oncology (talc pleurodesis)
- 3. Principles of discontinuation and bridging of anticoagulants
- 4. Principles of sedation
- 5. Sampling and handling of probes

## Module 12. Other sampling techniques

- 1. Pleural tap
- 2. Pleural needle biopsy
- 3. Chest tube insertion and management
- 4. Blind pleurodesis
- 5. Cytology Positivity Rates
- 6. False Negatives

## Module 13. Pathology

- 1. Basic principles of diagnostic steps in pathology related to thoracic malignancies
  - 1.1. light microscopy: Small cell carcinoma (SCC) vs non-small cell carcinoma (NSCLC), squamous vs non-squamous carcinoma, carcinoids
  - 1.2. role of immunohistochemistry
  - 1.3. molecular pathology: actionable mutations (EGFR, BRAF, MET, NTRK1, Her 2) and gene rearrangements (ALK, ROS1, RET), resistance mutations
- 2. Basic principles of proper handling of samples in suspected thoracic malignancies
- 3. Tissue preservation and quality of samples (adequate tumour contents) for light microscopy, immunohistochemistry and molecular pathology (DNA and RNA studies)
- 4. Liquid biopsy (cell free DNA, circulating tumour DNA)

## Module 14. Evaluation of patient fitness for diagnostics and therapy

1. Basic principles of evaluation of patient fitness for diagnostics and therapy

#### Module 15. Multidisciplinary team and multidisciplinary team meeting

- 1. Importance of multidisciplinary teamwork throughout the continuum of thoracic malignancies
- 2. Multidisciplinary team meeting as the hallmark of decision-making in the process of care for patients with thoracic malignancies
- 3. Quality requirements and monitoring for diagnosis, treatment and follow-up

#### Module 16. Thoracic surgery

- 1. Basic principles and indications of thoracic surgery in thoracic oncology
- 2. Types of thoracic surgery
- 3. Role of thoracic surgery in diagnosis as well as curative and palliative treatment

#### Module 17. Radiotherapy

- 1. Basic principles and indications of radiotherapy in thoracic oncology
  - 1.1 Tomotherapy, stereotactic body radiotherapy (SBRT), proton therapy
  - 1.2 Quality monitoring and guidelines for safety
  - 1.3 Irradiation of extra thoracic disease with its specific complications/side effects
- 2. Role of radiotherapy in curative and palliative treatment





## Module 18. Systemic pharmacotherapy

- 1. Basis of cytotoxic therapy and biological/targeted therapy
  - 1.1. Describe the basic principles of chemotherapy and biological/targeted therapy as well as drug toxicities
- 2. Indications and contraindications for systemic therapy including chemotherapy and targeted agents
  - 2.1. Non-small cell lung carcinoma (NSCLC)
  - 2.2. Small cell lung cancer (SCLC)
  - 2.3. Mesothelioma
  - 2.4. Thymoma
  - 2.5. Other mediastinal tumours

#### Module 19. Immunotherapy

- 1. Basic principles and methods of cancer immunotherapy
- 2. Indications and contraindications for immunotherapy including combination therapy with chemotherapies
- 3. NSCLC
- 4. SCLC
- 5. Mesothelioma
- 6. Describe the basic principles of immunotherapy planning

#### Module 20. Rehabilitation

- 1. Basic principles and indications of rehabilitation programmes
- 2. Value of rehabilitation programmes in the pre-operative setting as well as after completion of tumour-specific therapy

## Module 21. Smoking prevention and cessation

- 1. Effects of smoking, heated tobacco products and smokeless tobacco products as well as other smoked or vape-related products on the health of the individual in relation to thoracic oncology
- 2. Beneficial effects of smoking cessation for preventing thoracic malignancies as well as during and after treatment of thoracic malignancies
- 3. Treatment modalities for smoking cessation

# Module 22. Palliative care including treatment of tumour-related symptoms and complications

- 1. Basic principles of palliative care in thoracic oncology including its early integration as well as end-of-life care
- 2. Basic principles and options regarding treatment of the following tumour-related symptoms and complications:
  - 2.1. Dyspnoea
  - 2.2. Pain
  - 2.3. Tracheobronchial stenosis
  - 2.4. Haemoptysis
  - 2.5. Cough
  - 2.6. Sialorrhea
  - 2.7. Nausea/vomiting
  - 2.8. Seizures
  - 2.9. Pathologic fractures
  - 2.10. Vertebroplasty
  - 2.11. Vena cava syndrome
- 3. Treatment of pleural disease
  - 3.1. Talc pleurodesis
  - 3.2 IPC
  - 3.3 Surgery

# Module 23. Patient and family support

1. Teach the patient to recognise early side effects and to contact his/her physician





2. Importance of a multidisciplinary team for both acknowledgement of the patient and provision of care and surveillance

#### Module 24. Management of paraneoplastic syndromes

- 1. Basic principles of management of the following paraneoplastic syndromes:
  - 1.1. Cachexia
  - 1.2. Hypercalcemia
  - 1.3. Thromboses and pulmonary embolism
  - 1.4. Syndrome of inappropriate antidiuretic hormone (hyponatremia)
  - 1.5. Ectopic adrenocorticotropic hormone syndrome
  - 1.6. Lambert-Eaton syndrome and other neurological disorders (e.g.anti-HU associated symptoms)
  - 1.7. Clubbing and periostitis
- 2. Awareness that the presence of paraneoplastic syndromes *per se* does not exclude curative treatment in thoracic oncology

# Module 25. Thromboembolic disease in thoracic oncology

- 1. Prevention of thromboembolism in thoracic oncology
- 2. Diagnostic and therapeutic management of thrombosis and pulmonary embolism in thoracic oncology

## Module 26. Thoracentesis including a chest tube and a tunnelled indwelling pleural catheter

- 1. Indications, contraindications, limitations and benefit-risk assessment as well as quality aspects for thoracentesis including a chest tube and a tunnelled indwelling pleural catheter
- 2. Principles of discontinuation and bridging of anticoagulants
- 3. Principles of sedation

# Module 27. Common side effects of systemic therapies and their management

- 1. Side effects of chemotherapy and their management
  - 1.1. Haematological side effects: neutropenia, febrile neutropenia, anaemia and thrombopenia
  - 1.2. Mucositis/oesophagitis
  - 1.3. Alopecia and dermatological toxicity
  - 1.4. Nausea, vomiting and diarrhoea
  - 1.5. Neurotoxicity
  - 1.6. Ototoxicity
  - 1.7. Hepatic toxicity
  - 1.8. Nephrotoxicity
  - 1.9. Cardiovascular toxicity
  - 1.10. Extravasation: infertility and teratogenesis
  - 1.11. Electrolyte imbalance
  - 1.12. Side effect in patients with thoracic oncological disease treated with systemic therapy
- 2. Side effects of targeted therapy and their management
  - 2.1. Dermatological toxicity
  - 2.2. Diarrhoea
  - 2.3. Hepatic toxicity
  - 2.4. Cardiovascular toxicity
  - 2.5. Pulmonary toxicity
  - 2.6. Nephrotoxicity
- 3. Side effects of immunotherapy and their management
  - 3.1. Pneumonitis
  - 3.2. Dermatological toxicities
  - 3.3. Hepatic toxicity
  - 3.4. Cardiovascular toxicity (e.g. myocarditis)
  - 3.5. Endocrinological toxicities
  - 3.6. Nephrotoxicity
  - 3.7. Neurological toxicities





- 3.8. Side effect in patients with thoracic oncological disease treated with immunotherapy
- 3.9. Hematologic toxicity
- 4. Oncologic therapies in the context of viral pandemics

# Module 28. Common radiation-induced side effects and their management

- 1. Radiation-induced pneumonitis (short-term) and fibrosis (long-term)
- 2. Radiation-induced oesophagitis
- 3. Cardiac toxicity
- 4. Tracheal complications
- 5. Skin reactions
- 6. Secondary malignancy
- 7. Radiation-induced side effect in patients with thoracic malignancies treated with radiotherapy
- 8. Risk of radiotherapy-induced malignancies
- 9. Risk of radiation-induced malignancies

# Module 29. Solitary pulmonary nodules

- 1. Basic principles of solitary pulmonary nodule management including radiological characteristics as well as core diagnostic and follow-up strategies
- 2. Up-to-date guidelines for the management of solitary pulmonary nodules

#### Module 30. Malignant pleural mesothelioma

1. Basic principles of diagnostic (recommended procedures and histopathology) and therapeutic management of malignant pleural mesothelioma including multi-modal treatment modalities

#### Module 31. Mediastinal tumours

1. Basic principles of diagnostic and therapeutic management of common mediastinal tumours (thymoma and lymphoma)

## Module 32. Common metastatic pulmonary tumours

1. Metastatic pulmonary tumours as a differential diagnosis of pulmonary nodules/masses (*e.g.* pulmonary metastasis in thyroid, colorectal, prostate, renal or mammary gland carcinoma as well as soft tissue sarcoma and osteogenic sarcoma)

## Module 33. Malignant pleural effusion

1. Basic principles of diagnostic and therapeutic management of malignant pleural effusion